Identifying HER2 from serum-derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab-based therapy.
Qian LiMinzhi LvLihua LvNida CaoAiguang ZhaoJiayan ChenXi TangRongkui LuoShan YuYan ZhouYuehong CuiWei GuoTianshu LiuPublished in: Cancer medicine (2022)
Serum exosomal HER2 level might serve as an effective biomarker for assessing tissue HER2 status in AGC and screening the potential patients who might benefit from anti-HER2 therapy.